Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ellen Potter is active.

Publication


Featured researches published by Ellen Potter.


Frontiers in Neuroendocrinology | 1995

Corticotropin Releasing Factor (CRF) Binding Protein: A Novel Regulator of CRF and Related Peptides

Dominic P. Behan; Errol B. De Souza; Philip J. Lowry; Ellen Potter; Paul E. Sawchenko; Wylie Vale

A 37-kDa corticotropin releasing factor (CRF) binding protein (CRF-BP) was purified from human plasma by repeated affinity purification and subsequently sequenced and cloned. The human and rat CRF-BP cDNAs encode proteins of 322 amino acids with one putative signal sequence, one N-glycosylation site, and 10 conserved cysteines. Human CRF-BP binds human CRF with high affinity but has low affinity for the ovine peptide. In contrast, sheep CRF-BP binds human and ovine CRF with high affinity. The CRF-BP gene consists of seven exons and six introns and is located on chromosome 13 and loci 5q of the mouse and human genomes, respectively. CRF-BP inhibits the adrenocorticotrophic hormone (ACTH) releasing properties of CRF in vitro. CRF-BP dimerizes after binding CRF and clears the peptide from blood. This clearance mechanism protects the maternal pituitary gland from elevated plasma CRF levels found during the third trimester of human pregnancy. CRF-BP is expressed in the brains of all species so far tested but is uniquely expressed in human liver and placenta. In brain, CRF-BP is membrane associated and is predominantly expressed in the cerebral cortex and subcortical limbic structures. In some brain areas CRF-BP colocalizes with CRF and CRF receptors. The protein is also present in pituitary corticotropes, where it is under positive glucocorticoid control, and is likely to locally modulate CRF-induced ACTH secretion. The ligand requirements of the CRF receptor and the CRF-BP can be distinguished in that central human CRF fragments, such as CRF (6-33) and CRF (9-33), have high affinity for CRF-BP but low affinity for the CRF receptor. The binding proteins ability to inhibit CRF-induced ACTH secretion can be reversed by CRF (6-33) and CRF (9-33), suggesting that ligand inhibitors may have utility in elevating free CRF levels in disease states associated with decreased CRF. Thus, by controlling the amount of free CRF which activates CRF receptors, it is likely that the CRF-BP is an important modulator of CRF both in the CNS and in the periphery.


Proceedings of the National Academy of Sciences of the United States of America | 1994

Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary

Ellen Potter; Steven W. Sutton; Cynthia J. Donaldson; Ruoping Chen; Marilyn H. Perrin; Kathy A. Lewis; Paul E. Sawchenko; Wylie Vale


Proceedings of the National Academy of Sciences of the United States of America | 1992

The central distribution of a corticotropin-releasing factor (CRF)-binding protein predicts multiple sites and modes of interaction with CRF.

Ellen Potter; Dominic P. Behan; Elizabeth A. Linton; Philip J. Lowry; Paul E. Sawchenko; Wylie Vale


The Journal of Clinical Endocrinology and Metabolism | 1993

Corticotropin-releasing factor-binding protein is produced by human placenta and intrauterine tissues

Felice Petraglia; Ellen Potter; V A Cameron; Steve Sutton; Dominic P. Behan; R J Woods; Paul E. Sawchenko; Philip J. Lowry; Wylie Vale


Molecular Endocrinology | 1990

Inhibition of somatotroph growth and growth hormone biosynthesis by activin in vitro

Nils Billestrup; Consuelo Gonzalez-Manchon; Ellen Potter; Wylie Vale


Genomics | 1993

Cloning and structure of the human corticotrophin releasing factor-binding protein gene (CRHBP)

Dominic P. Behan; Ellen Potter; Kathy A. Lewis; Nancy A. Jenkins; Neal G. Copeland; Philip J. Lowry; Wylie Vale


Annals of the New York Academy of Sciences | 1993

Corticotropin‐Releasing Factor‐Binding Protein A Putative Peripheral and Central Modulator of the CRF Family of Neuropeptidesa

Dominic P. Behan; Ellen Potter; Steve Sutton; Wolfgang H. Fischer; Philip J. Lowry; Wylie Vale


Annals of the New York Academy of Sciences | 1996

Modulatory Actions of Corticotropin‐releasing Factor–binding Proteina

Dominic P. Behan; Errol B. De Souza; Ellen Potter; Paul E. Sawchenko; Philip J. Lowry; Wylie Vale


Archive | 1995

CRF binding protein antibodies and assays using same

Ellen Potter; Dominic P. Behan; Elizabeth A. Linton; Philip J. Lowry; Wylie Vale


Archive | 1993

CRF binding protein

Ellen Potter; Dominic P. Behan; Wolfgang H. Fischer; Elizabeth A. Linton; Philip J. Lowry; Wylie Vale

Collaboration


Dive into the Ellen Potter's collaboration.

Top Co-Authors

Avatar

Wylie Vale

Salk Institute for Biological Studies

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Wolfgang H. Fischer

Salk Institute for Biological Studies

View shared research outputs
Top Co-Authors

Avatar

Paul E. Sawchenko

Salk Institute for Biological Studies

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kathy A. Lewis

Salk Institute for Biological Studies

View shared research outputs
Top Co-Authors

Avatar

Errol B. De Souza

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Nancy A. Jenkins

Houston Methodist Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge